Attention Deficit Hyperactivity Disorder Pipeline Analysis Report 2025

Report Coverage

The Attention Deficit Hyperactivity Disorder Pipeline Analysis Report by Expert Market Research gives comprehensive insights into attention deficit hyperactivity disorder therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for attention deficit hyperactivity disorder. The attention deficit hyperactivity disorder report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The attention deficit hyperactivity disorder pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with attention deficit hyperactivity disorder treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to attention deficit hyperactivity disorder.

Attention Deficit Hyperactivity Disorder Pipeline Outlook

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental condition marked by inattention, hyperactivity, and impulsivity. It typically emerges in childhood and may persist into adulthood. ADHD occurs due to genetic, neurobiological, and environmental factors that affect brain development and neurotransmitter function, particularly in areas controlling attention and behavior regulation.

ADHD treatment includes behavioral therapy and medications. Stimulants like methylphenidate and non-stimulants such as atomoxetine or clonidine help improve focus and control impulsive behaviors. For instance, in May 2024, Tris Pharma received U.S. FDA approval for ONYDA XR, a once-daily, extended-release oral suspension of clonidine hydrochloride, offering the first liquid non-stimulant ADHD treatment with nighttime dosing.

Attention Deficit Hyperactivity Disorder Epidemiology

According to a 2023 global study, attention deficit hyperactivity disorder (ADHD) affects 7.6% of children aged 3–12 years and 5.6% of adolescents aged 12–18 years. In the United States, the Centers for Disease Control and Prevention reported that 11.4% of children aged 3–17 years (approximately 7 million) had been diagnosed with ADHD as of 2022. In the United Kingdom, adult ADHD prevalence is estimated at 3% to 4%.

Attention Deficit Hyperactivity Disorder – Pipeline Therapeutic Assessment

Attention Deficit Hyperactivity Disorder Pipeline Assessment Segmentation by Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share (34.09%) of the total attention deficit hyperactivity disorder clinical trials. It is followed by Phase IV at 31.82%, Phase III at 18.18%, Phase I at 11.36%, and Early Phase I at 4.55%. The robust presence of advanced and late-stage trials reflects strong R&D progress, indicating promising future approvals that can positively shape the attention deficit hyperactivity disorder market landscape.

Attention Deficit Hyperactivity Disorder Pipeline Assessment Segmentation by Drug Classes

The drug molecule categories covered under the attention deficit hyperactivity disorder pipeline analysis include small molecules, prodrugs, peptides, and biologics. The attention deficit hyperactivity disorder report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for attention deficit hyperactivity disorder.

Non-stimulant therapies are gaining traction in the attention deficit hyperactivity disorder (ADHD) pipeline. For example, in December 2024, Qelbree (viloxazine extended-release), a novel serotonin-norepinephrine modulating agent, has been submitted for review in Canada by Knight Therapeutics. It is currently approved in the United States and is undergoing further clinical evaluation for various age groups and comorbid conditions, offering an alternative to traditional stimulants.

Attention Deficit Hyperactivity Disorder Clinical Trials – Key Players

The EMR report for the attention deficit hyperactivity disorder pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed attention deficit hyperactivity disorder therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in attention deficit hyperactivity disorder clinical trials:

• Otsuka Pharmaceutical Development & Commercialization, Inc.
• Corium, Inc.
• Supernus Pharmaceuticals, Inc.
• Ironshore Pharmaceuticals and Development, Inc.
• Neurocentria, Inc.
• Bazelet Nehushtan Ltd.
• Shanghai Ark Biopharmaceutical Co., Ltd.
• Premier Research Group plc.
• Prometrika, LLC
• Takeda Development Center Americas, Inc.

Attention Deficit Hyperactivity Disorder – Emerging Drugs Profile

Reasons To Buy This Report

The Attention Deficit Hyperactivity Disorder Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for attention deficit hyperactivity disorder. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within attention deficit hyperactivity disorder pipeline insights.

Key Questions Answered in the Attention Deficit Hyperactivity Disorder Pipeline Analysis Report

• Which companies/institutions are leading the attention deficit hyperactivity disorder drug development?
• What is the efficacy and safety profile of attention deficit hyperactivity disorder pipeline drugs?
• Which company is leading the attention deficit hyperactivity disorder pipeline development activities?
• What is the current attention deficit hyperactivity disorder commercial assessment?
• What are the opportunities and challenges present in the attention deficit hyperactivity disorder pipeline landscape?
• What is the efficacy and safety profile of attention deficit hyperactivity disorder pipeline drugs?
• Which company is conducting major trials for attention deficit hyperactivity disorder drugs?
• Which companies/institutions are involved in attention deficit hyperactivity disorder collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in attention-deficit hyperactivity disorder?

Related Reports

Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Report

Global Clinical Trials Market